Sitagliptin (brand name Januvia®)
Patents that originally covered the drug, its uses, and specific formulations, were filed by Merck & Co. in the early‑2000s and have now all expired or been superseded.
| Patent (US) |
Key Claim(s) |
Filed |
Expiry (US) |
Notes |
| US 6,381,374 |
“Composition of matter” (sitagliptin) |
2001 |
2016‑04‑18 |
First core composition patent – expired before generic launch. |
| US 6,752,731 |
“Pharmaceutically acceptable salt of sitagliptin” |
2003 |
2018‑03‑11 |
Covers salt forms (e.g., sitagliptin fumarate). |
| US 7,091,892 |
“Sitagliptin and its use in treating type 2 diabetes” |
2005 |
2018‑03‑11 |
Claims therapeutic use; same expiry as the salt patent. |
| US 7,238,596 |
“Methods of using sitagliptin in combination therapy” |
2007 |
2019‑04‑03 |
Combination‑therapy claims; expired in 2019. |
| US 8,002,892 |
“Immediate‑release tablets of sitagliptin” |
2009 |
2021‑07‑21 |
Formulation patent that lasted until 2021. |
| US 9,147,795 |
“Sustained‑release tablets of sitagliptin” |
2010 |
2023‑10‑20 |
Latest formulation patent, expires in 2023. |
Bottom line: All of Merck’s U.S. patents that are enforceable for sitagliptin have expired (the most recent one – a sustained‑release formulation – expires in October 2023). After a patent expires, generic manufacturers are free to apply for approval and launch their versions, subject to the usual FDA review.
How this translates to the market
| Year |
Milestone |
| 2006 |
FDA approves Januvia® (sitagliptin) for type 2 diabetes. |
| 2019 |
First U.S. generic approvals (Mylan, Teva, etc.) – a consequence of the 30‑month exclusivity period ending for the key therapeutic‑use patents. |
| 2021 |
Expiry of the “immediate‑release tablet” patent; a number of generics that had been waiting for this milestone enter the market. |
| 2023 |
Final formulation patent (sustained‑release) expires; additional generic competitors can now launch new tablet strengths or dosage‑formulations. |
Current status: The brand name Januvia® is still sold in the U.S. and EU, and Merck retains marketing exclusivity on the original branded product. However, a wide range of generic sitagliptin products are already available, and additional generics that use newer formulations will become available as soon as the last patent (2023) expires.
International situation
| Region |
Key patent expiry |
Notes |
| European Union |
2024–2026 (depending on the specific application) |
EU patents on the composition of matter and use are typically 20 years from filing; the latest EU grant is 2015, so expiry falls in the 2025‑2026 window. |
| Canada |
2021‑2023 |
Similar to the U.S. schedule; many generics launched in 2019–2020. |
| Australia |
2023‑2024 |
Patents were granted in 2015‑2017; expire 20 years from filing. |
Bottom line: In most major markets, the core patents on sitagliptin are either expired or about to expire, giving the generic market a growing share of the drug.
Take‑away for patients and prescribers
- Cost – Once a drug’s core patents expire, generic versions are typically available at a fraction of the branded price.
- Quality – Generic sitagliptin products meet the same FDA (or EMA) standards for efficacy, safety, and bioequivalence.
- Prescribing – Clinicians can safely switch patients from Januvia® to a generic formulation without compromising therapeutic outcomes.
If you’re a prescriber or patient wondering whether a particular generic is available, check the drug’s status on the FDA’s “Approved Drug Products with Therapeutic Equivalence Evaluations” list (often called the Purple Book) or the EMA’s “Medicines for Human Use” database.
Disclaimer
The information above reflects the latest publicly available data as of July 2026. Patent status can change if new claims are filed or legal challenges arise, so for critical decisions (e.g., commercial launch, patent litigation) you should consult a qualified intellectual‑property attorney or the latest USPTO/DPMA/EMA filings.